“Grove has been an essential part of 3D Signals since its inception and instrumental in opening doors to leading Industry 4.0 multinationals”
Ariel Rosenfeld, CEO
3DSignals
“Grove's founders-first approach has been fundamental for building Env0 from the first day, helping us constantly and creating value”
Ohad Maislish, CEO
Env0
“Grove’s broad industry networking and deep operational experience helped us shape our plans and connect with customers and partners”
Tal Tamir, CEO
Wiliot
“Grove are very active in helping us tackle crucial challenges and helping us to recruit top notch people as part of our team”
Erez Berkner, CEO
Lumigo
“Grove’s team listen, support and make us think outside the box. They are fully committed to our success and became an indispensable part of our team”
Avi Veidman, CEO
Nucleai
“Grove is always there to guide us through difficulties, dilemmas and the endless challenges that arise during the process of creating a deep tech venture”
Avi Bakal, CEO
Trieye
“Grove have turned the world around for us.
Their nonstop - hard work - push forward attitude is something every entrepreneur should have by his side”
Elad Sity, CEO
Neuroblade
Focusing on Deep Tech
Innovate!
Grove Ventures is a venture capital fund in Israel with an emphasis on Deep Technology.
We lead the deep-tech innovation in Israel by empowering passionate founders.
Those who are determined to shape the future and our lives through cutting-edge technology.
This is not a short sprint but a long marathon.
We are prepared to accompany, guide and support you for the long run through thick and thin.
Working for You
Just Ask!
With our direct approach and global experience, we'll roll up our sleeves, work hand in hand with you from inception through growth and lead you through the path to global market leadership.
Insights
env0 Announces $3.5 Million in Seed Extension from M12 and Crescendo
15 Jul 2020 | Tech.eu
The new funding will be used to accelerate R&D for its self-service cloud management platform
AI cancer treatment startup Nucleai raises $6.5 million in series A round
08 Jul 2020 | Calcalist
Nucleai’s software uses computer vision and machine learning algorithms to predict the progress of cancerous tumors as well as the patient’s immune system response in order to determine the most efficient treatment
Contact Us
